This phase II trial compares standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone to consolidation with teclistamab following standard induction therapy and autologous hematopoietic stem cell transplant for improving overall survival of patients with plasma cell leukemia. Consolidation therapy is treatment given after initial therapy to kill any cancer cells that may remain in the body. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells, including myeloma cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Carfilzomib inhibits protein complexes called proteasomes, which inhibits cancer cell growth and leads to cancer cell death. Lenalidomide may help kill cancer cells and prevents the growth of blood vessels that cancer cells need to survive. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Teclistamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Giving teclistamab as consolidation therapy after induction and autologous hematopoietic stem cell transplant may improve survival outcomes in patients with plasma cell leukemia, compared to standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone.

开始日期2027-04-20

申办/合作机构

National Cancer Institute

NCT07715903

/ Not yet recruiting临床1期IIT

Phase I Study Evaluating Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy

Background:
Cancers that begin in the colon, adrenal glands, or bile ducts may spread to the liver. These liver tumors are often treated using a hepatic artery infusion (HAI) pump. The HAI pump is installed in the artery that goes to the liver; drugs are administered directly to the liver through this pump. But these tumors often return after treatment. Carfilzomib (CFZ) is a drug approved to treat another kind of cancer. Researchers want to find out if this drug may be helpful when administered through the HAI pump directly to the liver for people with colon, adrenal glands, or bile duct cancer that has spread to the liver.
Objective:
To test the safety of carfilzomib (CFZ) delivered via a hepatic artery infusion (HAI) pump directly to the liver in people with cancer in their liver.
Eligibility:
People aged 18 years or older with cancers of the colon, adrenal glands, or bile ducts that spread to the liver and persist after treatment. They must have a functioning hepatic artery infusion (HAI) pump in place from previous treatment of HAI pump therapy.
Design:
Participants will be screened. They will have a physical exam, blood tests, imaging scans, and a test of their heart function. They will also have a test to show how the blood flows through their liver: A radioactive substance will be injected into a vein, and a special camera will take pictures of the blood flow for up to 1 hour.
Participants will receive the study drug for about 6 months. They will visit the clinic once a week. Their HAI pump will be filled with the drug at each visit; the drug will slowly drain from the pump into the liver. Blood tests and imaging scans will be repeated during the study.
Participants will have follow-up visits 1 and 3 months after their last dose of study drug.
An optional liver biopsy (tissue sample) for research purposes may be done before the study drug is given, and again (optional) within 28 days after first receiving the study drug. Individuals may participate in the study even if they do not agree to have the biopsies done.
...

开始日期2026-10-27

申办/合作机构

National Cancer Institute

KCT0012128

/ Not yet recruiting临床2期IIT

Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) Combination Therapy in Patients with Relapsed and Refractory Multiple Myeloma

开始日期2026-08-01

申办/合作机构-

100 项与卡非佐米相关的临床结果

登录后查看更多信息

100 项与卡非佐米相关的转化医学

登录后查看更多信息

100 项与卡非佐米相关的专利（医药）

登录后查看更多信息

2,321

项与卡非佐米相关的文献（医药）

2027-05-01·Value in Health Regional Issues

Cost-Effectiveness Analysis of Carfilzomib vs Bortezomib in Relapsed/Refractory Multiple Myeloma in Iran

Article

作者: Raeis Zadeh, Mohammad Mahdi ; Fatemi, Behzad ; Mashreghi Mohammadi, Neshaut ; Nikfar, Shekoufeh

OBJECTIVES:

Multiple myeloma, the second most common hematologic malignancy, primarily affects older adults. Proteasome inhibitors such as carfilzomib and bortezomib are key treatment options. Because of high costs, disease progression, and differences in drug outcomes, cost-effectiveness evaluations are crucial for healthcare policy.

METHODS:

A model-based cost-effectiveness study was conducted using Partitioned Survival Analysis with clinical and quality-of-life data from the ENDEAVOR trial. A societal perspective and 20-year time horizon were applied, encompassing direct medical, nonmedical, and indirect costs, refined through expert consultation. Treatment effectiveness was measured using quality-adjusted life-years (QALYs), whereas incremental cost-effectiveness ratio was applied to determine cost-effectiveness. Costs and outcomes beyond the first year were discounted annually at 5.8% and 5%, respectively. The willingness-to-pay threshold was set at $6065.57 (1 Iranian gross domestic product/capita). To address model uncertainty, tornado diagrams, 1-way sensitivity analyses, and Monte Carlo simulations were performed.

RESULTS:

Carfilzomib was not cost-effective relative to bortezomib in treating relapsed/refractory multiple myeloma in Iran. Total treatment cost for carfilzomib reached $100 139.98 compared with $31 100.49 for bortezomib. Carfilzomib achieved higher health gains, with 3.43 QALYs vs 2.94 QALYs. However, its incremental cost was $69 039.49, yielding an incremental cost-effectiveness ratio of $139 206.61 per QALY gained.

CONCLUSION:

In the treatment of relapsed/refractory multiple myeloma in Iran, Carfilzomib demonstrates greater clinical effectiveness than Bortezomib but is associated with substantially higher costs. Despite its improved health outcomes, Carfilzomib does not meet cost-effectiveness criteria at current market prices.

2026-12-01·JOURNAL OF MOLECULAR MEDICINE-JMM

Anti-myeloma activity of the CXCR4 antagonist WZ811

Article

作者: Suroviakova, Katarina ; Sedlak, Jan ; Jakubikova, Jana ; Valuskova, Zuzana ; Strizova, Anna ; Marinkovicova, Maria Elisabeth ; Csicsatkova, Nikoleta ; Cholujova, Danka

Abstract:

The CXCR4-CXCL12 axis is crucial for the interaction between malignant plasma cells (PC) and their microenvironment in multiple myeloma (MM). Here, we show that CXCR4 expression is upregulated in MM cell lines and PCs during both premalignant and active stages of MM, compared to normal PCs from healthy donors. The CXCR4 antagonist WZ811 reduced the viability of MM PCs and cell lines, while tumor microenvironment cells from both MM patients and healthy donors exhibited significant resistance. In vivo, WZ811 significantly reduced tumor burden and improved survival. WZ811-mediated MM cell death involved disruption of mitochondrial transmembrane potential, externalization of transmembrane phosphatidylserine, activation of caspases, increased levels of autophagic proteins, and an increase in G 0 /G 1 phase of the cell cycle. WZ811 also eliminated the MM stem cell-like side population, though slight resistance was observed with stromal cells. Additionally, WZ811 increased levels of CXCL12 and extracellular matrix molecules collagen IV and laminin in MM cells. Combining WZ811 with anti-MM agents showed synergism with doxorubicin, dexamethasone, bortezomib, lenalidomide, and pomalidomide, while antagonism was observed with carfilzomib, supporting the clinical assessment of WZ811 in MM.

Key messages:

WZ811 reduced the viability of myeloma primary cells and cell lines.WZ811 reduced tumor burden and improved survival in vivo xenograft model.WZ811 mechanisms involved apoptotic and autophagic cell death.WZ811 eliminated the MM stem cell-like side population.WZ811 synergized with DOX, DEX, BTZ, LEN, and POM.

2026-11-01·BIOORGANIC & MEDICINAL CHEMISTRY

Non-covalent dual HDAC6/proteasome inhibitors with anti-multiple myeloma activity

Article

作者: Shi, Tingting ; Zhuang, Rangxiao ; Ke, Yunling ; Zhao, Yanmei ; Sun, Jingjing ; Shao, Yidan ; Zou, Xi

Multiple myeloma (MM) remains an incurable hematological malignancy, even with the clinical success of proteasome inhibitors (PIs). The compensatory upregulation of HDAC6 following proteasome inhibition offers a strong rationale for dual targeting. However, a systematic comparison of different zinc-binding groups (ZBGs) within a non-covalent scaffold has been lacking. Here, we designed a series of non-covalent dual HDAC6/proteasome inhibitors based on a carfilzomib-derived scaffold, incorporating either a hydroxamic acid or an ortho-aminoanilide ZBG with linkers of varying lengths. Our SAR analysis revealed a clear division of labor: the R¹ position dominates proteasome inhibition (IC₅₀ = 2.6-8.1 nM, comparable to MG-132 at 10.8 nM), whereas HDAC6 activity is highly dependent on the choice of ZBG and cap group. For instance, the ortho-aminoanilide ZBG confers potent HDAC6 inhibition only when paired with a 2-chlorobenzyl cap (IC₅₀ = 29.8 nM); with a tetralin cap, it is essentially inactive (IC₅₀ > 5 μM). In contrast, the hydroxamic acid ZBG delivers moderate HDAC6 activity (130-280 nM) across both cap groups. Among the nine compounds, H-07 emerged as the most balanced dual inhibitor, with proteasome IC₅₀ = 4.2 nM and HDAC6 IC₅₀ = 29.8 nM. In RPMI-8226 cells, H-07 increased ac-α-tubulin and ac-histone H3 levels and induced PARP cleavage-findings consistent with engagement of both HDAC6 and class I HDACs, in addition to the expected effects from proteasome inhibition. Molecular dynamics simulations provided plausible binding modes for both targets. Despite this promising in vitro profile, a substantial loss of potency was observed in cell-based functional assays: the cellular proteasome IC₅₀ of H-07 was 6.768 μM, representing a > 1600-fold increase relative to its enzymatic IC₅₀ (4.2 nM). This marked shift is consistent with the limited membrane permeability frequently associated with polar peptidomimetic scaffolds, and it underscores a key limitation that must be addressed in future optimization efforts. Nevertheless, this work establishes a clear SAR framework and identifies key determinants for the rational optimization of this class of non-covalent dual inhibitors.

978

项与卡非佐米相关的新闻（医药）

2026-10-23

·求实药社

强生抗体新药在中国获批新适应症，针对多发性骨髓瘤

来源：医药观澜 10月22日，强生公司（Johnson & Johnson）宣布，中国国家药品监督管理局（NMPA）已批准泰立珂®（特立妥单抗注射液）新增适应症，用于既往至少接受过一线治疗（包括抗CD38单克隆抗体和来那度胺）的复发或难治性多发性骨髓瘤成人患者。特立妥单抗注射液是即用型的皮下注射双特异性抗体。该药物具有双结合位点，可将CD3+T细胞重定向到表达BCMA的骨髓瘤细胞，从而激活人体免疫系统以诱导杀伤肿瘤细胞。尽管多发性骨髓瘤一线治疗取得了重大进展，包括以抗CD38单抗为基础的四药联合方案，但大多数患者最终仍面临疾病复发。一旦患者对主要治疗方案（如抗CD38单抗和来那度胺）产生耐药，其预后尤为不佳。该患者群体长期面临治疗选择有限、二线治疗路径复杂的困境，进一步凸显了对更多可广泛应用于临床实践的免疫治疗方案的迫切需求。此次获批是基于3期MajesTEC-9研究结果。该研究旨在评估特立妥单抗注射液相较于标准治疗，即泊马度胺、硼替佐米联合地塞米松（PVd）或卡非佐米联合地塞米松（Kd），用于既往接受过1至3线治疗（包括来那度胺和抗CD38单克隆抗体）的复发或难治性多发性骨髓瘤患者的疗效。在这一经多线治疗的人群中，85%的患者对抗CD38单克隆抗体耐药、79%对来那度胺耐药，以及超过90%对末次治疗耐药。研究显示，特立妥单抗注射液在无进展生存期（PFS）和总生存期（OS）方面均展现出具有临床意义和统计学显著性的获益。在以抗CD38单抗和来那度胺耐药患者为主的研究人群中，特立妥单抗注射液将疾病进展或死亡风险降低71%，死亡风险降低40%。此次获批使特立妥单抗注射液治疗前移至首次复发阶段，为中国复发或难治性多发性骨髓瘤患者带来免疫治疗新选择。免责声明：文章内容仅供参考，不构成投资建议。投资者据此操作，风险自担, 关于对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部。联系我们 SIT 2027 展位火热预定中！扫码立即咨询电话：13816031174 （同微信）赞助形式包括但不仅限于演讲席位、会场展位、会刊彩页、晚宴赞助、会议用品宣传等。点击此处“阅读全文”咨询更多精彩！

临床3期免疫疗法

2026-10-22

·医药观澜

强生抗体新药在中国获批新适应症，针对多发性骨髓瘤丨产业新闻

今日，强生公司（Johnson & Johnson）宣布，中国国家药品监督管理局（NMPA）已批准泰立珂®（特立妥单抗注射液）新增适应症，用于既往至少接受过一线治疗（包括抗CD38单克隆抗体和来那度胺）的复发或难治性多发性骨髓瘤成人患者。特立妥单抗注射液是即用型的皮下注射双特异性抗体。该药物具有双结合位点，可将CD3+T细胞重定向到表达BCMA的骨髓瘤细胞，从而激活人体免疫系统以诱导杀伤肿瘤细胞。尽管多发性骨髓瘤一线治疗取得了重大进展，包括以抗CD38单抗为基础的四药联合方案，但大多数患者最终仍面临疾病复发。一旦患者对主要治疗方案（如抗CD38单抗和来那度胺）产生耐药，其预后尤为不佳。该患者群体长期面临治疗选择有限、二线治疗路径复杂的困境，进一步凸显了对更多可广泛应用于临床实践的免疫治疗方案的迫切需求。此次获批是基于3期MajesTEC-9研究结果。该研究旨在评估特立妥单抗注射液相较于标准治疗，即泊马度胺、硼替佐米联合地塞米松（PVd）或卡非佐米联合地塞米松（Kd），用于既往接受过1至3线治疗（包括来那度胺和抗CD38单克隆抗体）的复发或难治性多发性骨髓瘤患者的疗效。在这一经多线治疗的人群中，85%的患者对抗CD38单克隆抗体耐药、79%对来那度胺耐药，以及超过90%对末次治疗耐药。研究显示，特立妥单抗注射液在无进展生存期（PFS）和总生存期（OS）方面均展现出具有临床意义和统计学显著性的获益。在以抗CD38单抗和来那度胺耐药患者为主的研究人群中，特立妥单抗注射液将疾病进展或死亡风险降低71%，死亡风险降低40%。此次获批使特立妥单抗注射液治疗前移至首次复发阶段，为中国复发或难治性多发性骨髓瘤患者带来免疫治疗新选择。参考资料：[1]泰立珂®（特立妥单抗注射液）在华获批用于治疗首次复发多发性骨髓瘤患者，为更早治疗阶段带来全球范围内同类首创的免疫治疗新选择.From https://mp.weixin.qq.com/s/jeArsSXtx3M_BgUiyKfDRg 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

2026-10-22

·美通社

泰立珂®（特立妥单抗注射液）在华获批用于治疗首次复发多发性骨髓瘤患者，为更早治疗阶段带来全球范围内同类首创的免疫治疗新选择

此次获批是基于III期MajesTEC-9研究结果 [1] 。针对既往至少接受过一线治疗（包括抗CD38单抗及来那度胺）的复发或难治性多发性骨髓瘤患者，泰立珂 ® 将疾病进展或死亡风险降低71%，死亡风险降低40% [2] 此次适应症拓展进一步丰富了泰立珂 ® 在疾病更早治疗阶段应用的循证医学证据北京 2026年10月22日 /美通社/ -- 强生公司今日宣布，国家药品监督管理局已批准泰立珂®（特立妥单抗注射液）新增适应症，用于既往至少接受过一线治疗（包括抗CD38单克隆抗体和来那度胺）的复发或难治性多发性骨髓瘤成人患者 [1] 。此次获批是基于III期MajesTEC-9研究结果 [1] 。研究显示，泰立珂®在无进展生存期（PFS）和总生存期（OS）方面均展现出具有临床意义和统计学显著性的获益 [2] 。在以抗CD38单抗和来那度胺耐药患者为主的研究人群中，泰立珂®将疾病进展或死亡风险降低71%，死亡风险降低40% [2] 。此次获批使泰立珂®治疗前移至首次复发阶段，为中国复发或难治性多发性骨髓瘤患者带来全球范围内同类首创 [3] 的免疫治疗新选择。着力解决首次复发或难治性多发性骨髓瘤患者的临床未满足需求尽管多发性骨髓瘤一线治疗取得了重大进展，包括以抗CD38单抗为基础的四药联合方案，但大多数患者最终仍面临疾病复发 [4] 。一旦患者对主要治疗方案（如抗CD38单抗和来那度胺）产生耐药，其预后尤为不佳 [5] 。该患者群体长期面临治疗选择有限、二线治疗路径复杂的困境，进一步凸显了对更多可广泛应用于临床实践的免疫治疗方案的迫切需求 [3] 。重新定义多发性骨髓瘤患者的治疗新可能强生创新制药中国区总裁Cherry Huang女士表示："将特立妥单抗应用于更早的二线治疗阶段，有望显著改善患者的长期生存结局，并改变疾病进程，为患者及其家庭带来新的希望。随着特立妥单抗取得这一里程碑突破，我们正在推进一种可广泛应用的免疫治疗方式进入更早治疗阶段，帮助患者实现更深、更持久的缓解。在强生，我们始终秉持明确的使命，持续探索创新疗法和潜在治愈方案，致力于改善多发性骨髓瘤患者在疾病各阶段的治疗前景，向着治愈的未来不断前行。" III期MajesTEC-9研究结果显示，与标准治疗相比，更早使用泰立珂 ® 可显著改善无进展生存期和总生存期 MajesTEC-9研究旨在评估双特异性T细胞衔接抗体疗法泰立珂®相较于标准治疗，即泊马度胺、硼替佐米联合地塞米松（PVd）或卡非佐米联合地塞米松（Kd），用于既往接受过1至3线治疗（包括来那度胺和抗CD38单克隆抗体）的复发或难治性多发性骨髓瘤患者的疗效 [2] 。在这一经多线治疗的人群中，85%的患者对抗CD38单克隆抗体耐药、79%对来那度胺耐药，以及超过90%对末次治疗耐药 [2] 。与标准治疗相比，泰立珂®将疾病进展或死亡风险降低71%（风险比[HR]=0.29；95%置信区间[CI]：0.23-0.38），将死亡风险降低40%（HR=0.60；95% CI：0.43-0.83），在无进展生存期（PFS）和总生存期（OS）方面均取得显著改善 [2] 。此外，与标准治疗相比，泰立珂®在所有关键次要终点上均显示出显著改善，包括近三分之二的患者达到完全缓解或以上（≥CR；65.9% vs. 16.8%） [2] 。泰立珂®在该研究中的总体安全性特征与其已知安全性特征一致。与标准治疗相比，泰立珂®治疗期间出现的不良事件（TEAE）发生率相近（99.7% vs. 97.9%） [2] 。3/4级TEAE发生率分别为84.9%和76.3% [2] 。两组5级TEAE发生率均较低（6.5% vs. 3.5%） [2] 。两组中大多数5级TEAE均与感染相关（5.5% vs. 2.8%），且多数发生于治疗开始后的前6个月内 [2] 。在发生致死性感染的患者中，特立妥单抗组16例患者中有5例、PVd或Kd组8例患者中有6例未接受免疫球蛋白替代治疗；两组末次血清IgG水平低于400 mg/dL的患者分别为8例和2例 [2] 。与标准治疗相比，泰立珂®组感染发生率更高（3/4级：41.6% vs. 29.0%）；但随着疾病得到控制，3级及以上感染的发生率随时间推移而下降 [2] 。细胞因子释放综合征（CRS）发生于66.0%的泰立珂®治疗患者中，且大多数为1/2级，可通过标准管理措施进行处理 [2] 。所有CRS事件均已缓解，且未导致治疗终止 [2] 。免疫效应细胞相关神经毒性综合征（ICANS）发生率较低（4.1%），且主要为1/2级事件 [2] 。泰立珂®组的中位治疗持续时间接近标准治疗组的两倍（13.1个月 vs. 7.0个月） [2] 。关于特立妥单抗泰立珂 ® 是全球范围内同类首创、即用型的皮下注射双特异性抗体 [3] , [6] 。该药物具有双结合位点，可将CD3+T细胞重定向到表达BCMA的骨髓瘤细胞，从而激活人体免疫系统以诱导杀伤肿瘤细胞 [7] 。目前，特立妥单抗正在多项联合研究中开展进一步评估 [8] , [9] , [10] , [11] , [12] 。关于MajesTEC-9研究 [1] MajesTEC-9（NCT05572515）是一项正在开展的随机III期研究，旨在对比特立妥单抗单药方案与泊马度胺、硼替佐米联合地塞米松（PVd）或卡非佐米联合地塞米松（Kd），用于既往接受过1–3线治疗（包括来那度胺及抗CD38单抗）的复发或难治性多发性骨髓瘤患者的疗效。研究主要终点为无进展生存期（PFS）；次要终点包括完全缓解或更好的缓解（≥CR）、缓解持续时间（DoR）、至下次治疗时间（TTNT）、第二次无进展生存期（PFS2）、总生存期（OS）、安全性以及患者报告结局。关于多发性骨髓瘤多发性骨髓瘤是一种复杂的血液恶性肿瘤，累及骨髓内被称为浆细胞的白细胞 [13] 。在多发性骨髓瘤中，这类浆细胞异常增殖并快速扩散，形成肿瘤，取代骨髓内的正常细胞 [14] 。多发性骨髓瘤是全球第三大常见血液肿瘤 [15] ，每年全球新确诊病例超过18万例 [16] 。多发性骨髓瘤患者的五年生存率为59.8% [17] 。尽管部分患者在确诊时无明显症状，但大多数患者因出现骨折或骨痛、贫血相关症状、疲劳、高钙血症以及肾脏问题或感染等症状而被诊断 [18] , [19] 。近年来，随着治疗手段不断进步，多发性骨髓瘤患者的总生存期已从以"年"为单位延长至以"十年"为单位，目前在疾病各阶段及各治疗线别均已有有效的治疗选择 [20] 。关于强生创新制药作为首批进入中国的跨国制药企业之一，强生创新制药自1985年在华成立以来，始终致力于以科学领拓医药未来。科学为本，我们是忠于科学的创新者，积极探索突破性疗法，变革健康未来；使命为上，我们是健康中国的贡献者，以应对中国最为迫切的医药健康需求为己任，共筑健康中国；患者为先，我们是心系患者的同行者，不断创新治疗途径，帮助患者寻找治疗方法抵御疾病。作为强生在华制药子公司，我们聚焦于肿瘤学、免疫学、神经科学、心肺疾病、眼科等能够为人类健康带来巨大改变的疾病领域。关于前瞻性陈述的警示本新闻稿包含《1995年私人证券诉讼改革法案》所定义的关于泰立珂®（特立妥单抗注射液）的"前瞻性陈述"。请读者切勿过度依赖这些前瞻性陈述。这些陈述基于对未来事件的当前预期。如果基本假设被证明不准确，或者已知或未知的风险或不确定性成为现实，实际结果可能与强生公司的预期和预测存在重大差异。风险和不确定性包括但不限于：产品研发固有的挑战和不确定性，包括临床成功与获得监管批准的不确定性；商业成功的不确定性；生产困难和延误；竞争，包括技术进步、新产品以及竞争对手获得的专利；专利挑战；因产品疗效或安全性问题导致的产品召回或监管行动；医疗保健产品及服务购买者的行为和消费模式变化；适用法律法规的变化，包括全球医疗保健改革；以及医疗保健成本控制的趋势。有关这些风险、不确定性及其他因素的进一步列表和描述，可参见强生公司最新的Form 10-K 年报中的"关于前瞻性陈述的警示性声明"和"项目 1A. 风险因素"章节，以及强生公司后续向美国证券交易委员会提交的 Form 10-Q 季度报告和其他文件。这些文件的副本可在 www.sec.gov 、 www.jnj.com 线上获取或向强生公司索取。强生公司不承担因新信息、未来事件或发展而更新任何前瞻性陈述的义务。 [1] 特立妥单抗注射液说明书，2026年10月 [2] Costa LJ, et al. N Engl J Med. DOI: 10.1056/NEJMoa2514663. [3] Nooka AK, Rodriguez C, Mateos MV, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study. Cancer. 2024;130(6):886‐900. doi:10.1002/cncr.35107. [4] Rajkumar SV. Multiple Myeloma: 2026 Update on Diagnosis, Risk-Stratification and Management. Am J Hematol. 2026 Aug 18. doi: 10.1002/ajh.70475. Epub ahead of print. PMID: 42613778. [5] Ramasamy K, et. al. Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody. Clin Lymphoma Myeloma Leuk. 2025 May;25(5):337-348.e2. [6] Moreau P, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 2022;287(6):494-505. [7] Padala SA et al. Epidemiology, Staging, and Management of Multiple Myeloma. Med Sci (Basel). 2021;9(1):3. [8] European Medicines Agency. TECVAYLI Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf. Last accessed: March 2026. [9] ClinicalTrials.gov. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3). Available at: https://clinicaltrials.gov/study/NCT05083169. Last accessed: March 2026. [10] ClinicalTrials.gov. A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2). Available at: https://clinicaltrials.gov/ct2/show/NCT04722146. Last accessed: March 2026. [11] ClinicalTrials.gov. A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT04586426. Last accessed: March 2026. [12] ClinicalTrials.gov. A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT04108195. Last accessed: March 2026. [13] Rajkumar SV. Multiple Myeloma: 2020 Update on Diagnosis, Risk-Stratification and Management. Am J Hematol. 2020;95(5):548-567. [14] National Cancer Institute. Plasma cell neoplasms. Accessed May 2026. https://www.cancer.gov/types/myeloma/patient/myeloma-treatment-pdq [15] City of Hope. Multiple myeloma: Causes, symptoms & treatments. 2022. Accessed May 2026. https://www.cancercenter.com/cancer-types/multiple-myeloma [16] International Agency for Research on Cancer (World Health Organization). Multiple myeloma fact sheet. 2024. Accessed May 2026. https://gco.iarc.who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf [17] SEER Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute. Accessed May 2026. https://seer.cancer.gov/explorer/ [18] American Cancer Society. What is multiple myeloma? Accessed May 2026. https://www.cancer.org/cancer/multiple-myeloma/about/what-is-multiple-myeloma.html [19] American Cancer Society. Multiple myeloma early detection, diagnosis, and staging. Accessed May 2026. https://www.cancer.org/cancer/types/multiple-myeloma/detection-diagnosis-staging/detection.html [20] Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. J Clin Oncol. 2018;36(15):1479–1487. https://pmc.ncbi.nlm.nih.gov/articles/PMC6119139/

100 项与卡非佐米相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08880	卡非佐米	L01XG02	DB08889

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
多发性骨髓瘤	美国	Onyx Pharmaceuticals, Inc.	2012-07-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性多发性骨髓瘤	临床3期	美国	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	日本	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	奥地利	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	保加利亚	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	捷克	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	芬兰	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	法国	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	德国	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	希腊	Amgen, Inc.	2019-05-08
难治性多发性骨髓瘤	临床3期	立陶宛	Amgen, Inc.	2019-05-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02970747 (CARO, Pubmed \| Blut)	N/A	复发性多发性骨髓瘤	359	Carfilzomib with lenalidomide and dexamethasone (KRd)	蓋遞衊選襯膚鹹觸獵廠(襯襯繭夢製網夢顧夢範) = patients' adherence to carfilzomib was > 90% 選簾窪繭鑰遞餘醖艱鹽 (衊衊餘獵顧衊鏇觸糧遞 )	积极	2026-10-08
				Carfilzomib with dexamethasone only (Kd)
NCT05552976 (SUCCESSOR-2, IMS2026)	临床3期	复发性多发性骨髓瘤	479	Mezigdomide+Carfilzomib+Dexamethasone	繭夢衊鑰餘築窪壓衊顧(醖壓觸範襯積衊齋夢繭) = 鏇齋齋壓窪膚糧壓遞糧鏇壓構範遞鹽獵鬱衊鹹 (鏇範憲廠鹽願簾艱糧願 ) 更多	积极	2026-09-23
				Carfilzomib+Dexamethasone	繭夢衊鑰餘築窪壓衊顧(醖壓觸範襯積衊齋夢繭) = 夢淵範積積製廠願齋艱鏇壓構範遞鹽獵鬱衊鹹 (鏇範憲廠鹽願簾艱糧願 ) 更多
NCT05552976 (SUCCESSOR-2, IMS2026)	临床3期	复发性多发性骨髓瘤	371	Mezigdomide+Carfilzomib+Dexamethasone	齋選觸觸選選膚鏇構範(餘壓築艱餘廠齋繭壓顧) = 願憲鹽鏇廠醖網淵壓鏇鏇襯壓觸襯衊艱淵鹽鏇 (醖齋鑰蓋膚鹽鹹願襯廠 )	积极	2026-09-23
				Carfilzomib+Dexamethasone	齋選觸觸選選膚鏇構範(餘壓築艱餘廠齋繭壓顧) = 淵遞鬱鏇憲夢鑰鏇構鏇鏇襯壓觸襯衊艱淵鹽鏇 (醖齋鑰蓋膚鹽鹹願襯廠 )
NCT05552976 (SUCCESSOR-2, IMS2026)	临床3期	复发性多发性骨髓瘤	474	Mezigdomide+Carfilzomib+Dexamethasone	壓範觸廠顧蓋簾襯範艱(醖鹹鏇膚選獵窪鹹願膚) = 襯築選範製憲顧齋積糧網顧淵鬱獵觸網選觸構 (廠範鹹糧鹹顧製繭衊獵 ) 更多	积极	2026-09-23
				Carfilzomib+Dexamethasone	壓範觸廠顧蓋簾襯範艱(醖鹹鏇膚選獵窪鹹願膚) = 糧網顧襯願膚願廠廠蓋網顧淵鬱獵觸網選觸構 (廠範鹹糧鹹顧製繭衊獵 ) 更多
IMS2026	临床3期	多发性骨髓瘤	4	Carfilzomib-based regimens	壓襯淵蓋觸顧夢壓簾鏇(築選獵獵膚構製築淵構): OR = 1.26 (95.0% CI, 0.95 ~ 1.67) 更多	积极	2026-09-23
				Bortezomib-based regimens
IMS2026	N/A	多发性骨髓瘤	77	Carfilzomib, Pomalidomide, and Dexamethasone (KPd)	壓憲選淵淵遞夢鹽選顧(遞艱鑰糧餘艱繭願鹹積) = 鬱鹽鏇窪窪觸鏇構齋齋鏇積窪艱積構衊憲製選 (淵繭艱壓遞鬱衊蓋獵簾 ) 更多	积极	2026-09-23
				Carfilzomib, Pomalidomide, and Dexamethasone (KPd) (switch because of suboptimal early response)	願醖廠鬱夢餘鏇齋積鏇(廠膚鹹廠遞製積繭範網) = 範構願糧蓋鏇窪壓鬱網築積鹹憲壓鑰繭製製鏇 (夢鹽簾餘鏇鏇選積淵餘 ) 更多
IMS2026	N/A	多发性骨髓瘤一线	30	Carfilzomib	繭憲憲淵選襯蓋糧鏇憲(窪醖窪築餘憲糧艱網積) = patients' overall quality of life improved (P< 0.001). Significant improvements were observed in physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning. 膚觸膚築壓範築鏇夢襯 (鬱積憲製窪鏇網範艱淵 ) 更多	积极	2026-09-23
IMS2026	N/A	多发性骨髓瘤	113	Carfilzomib+dexamethasone+cyclophosphamide	糧願繭製網窪鹹鹽網繭(願簾鏇觸觸簾壓襯網淵) = 鏇鬱憲鹹顧艱鹹繭廠繭獵鬱鏇鏇醖蓋憲淵願餘 (簾獵鹹築蓋築衊獵艱膚, 3.9 ~ 9.4) 更多	积极	2026-09-23
				Carfilzomib+dexamethasone+pomalidomide	-
NCT05199311 (IMS2026)	临床1/2期	多发性骨髓瘤	58	Carfilzomib+Iberdomide+Dexamethasone	簾鹽鏇選遞餘簾選獵製(範選顧艱夢糧齋夢鹽願) = 齋顧鹽願遞鏇範鑰範鏇顧餘繭膚餘鬱淵遞憲顧 (壓窪鹽夢構淵窪選衊艱 ) 更多	积极	2026-09-23
				Carfilzomib+Iberdomide+Dexamethasone (high-risk subset)	簾鹽鏇選遞餘簾選獵製(範選顧艱夢糧齋夢鹽願) = 鹹憲願廠廠廠築淵餘醖顧餘繭膚餘鬱淵遞憲顧 (壓窪鹽夢構淵窪選衊艱 ) 更多
NCT05552976 (SUCCESSOR-2, EHA2026)	临床3期	复发性多发性骨髓瘤	479	Mezigdomide 1.0 mg + Kd	糧壓鏇夢觸觸餘獵餘淵(壓膚鏇積衊襯憲齋鹹壓) = 窪鑰艱鏇夢觸壓憲廠齋憲獵鏇膚簾窪遞範窪製 (衊築醖築簾願餘積選糧 ) 更多	积极	2026-06-02
				Kd	糧壓鏇夢觸觸餘獵餘淵(壓膚鏇積衊襯憲齋鹹壓) = 獵網製鏇簾觸淵膚觸觸憲獵鏇膚簾窪遞範窪製 (衊築醖築簾願餘積選糧 ) 更多